广发港股创新药ETF联接(QDII)C(019671)财务指标
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 本期已实现收益 |
-60,430,454.29 |
27,984,264.56 |
5,358,440.50 |
691,962.86 |
| 本期利润 |
-323,625,237.02 |
-287,595,316.70 |
59,253,775.90 |
757,269.74 |
| 加权平均基金份额本期利润 |
-0.16 |
-0.33 |
0.31 |
0.02 |
| 本期加权平均净值利润率(%) |
-12.62 |
-24.02 |
30.05 |
2.11 |
| 本期基金份额净值增长率(%) |
-10.83 |
59.07 |
51.25 |
-11.79 |
| 期末可供分配利润 |
-56,172,289.10 |
2,651,660.89 |
-10,199,720.40 |
-19,289,385.16 |
| 期末可供分配基金份额利润 |
-0.03 |
0.00 |
-0.02 |
-0.21 |
| 期末基金资产净值 |
2,201,433,405.13 |
2,471,710,989.07 |
650,864,466.34 |
71,992,500.64 |
| 期末基金份额净值 |
1.12 |
1.25 |
1.19 |
0.79 |
| 基金份额累计净值增长率(%) |
11.87 |
25.46 |
19.29 |
-21.13 |
微信公众号
证券之星APP
基本资料
